Abstract
An expert panel has concluded that more research is needed before circulating tumor DNA analyses are adopted in clinical care. This finding may slow the use of such testing among oncologists, some of whom are already basing treatment decisions on the results of these assays.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.